Search Results
Your search for ,itS matches 8694 pages
Showing 451 - 500Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?
Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of...
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...
Genomic Study Reveals Similarities, Differences in Ovarian Cancer Mutations Among Black, White Patients
Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research....
Enfortumab Vedotin Plus Pembrolizumab Continues to Show Benefit in Metastatic Urothelial Carcinoma
In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated...
Nivolumab Plus Cabozantinib Continues to Show Superior Long-Term Outcomes in Advanced Renal Cell Carcinoma
The PD-1 inhibitor nivolumab plus the tyrosine kinase inhibitor cabozantinib continues to demonstrate a significant survival advantage over sunitinib alone in patients with previously untreated advanced renal cell carcinoma, according to data presented at the 2025 ASCO Genitourinary Cancers...
Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop
Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...
Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma
The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...
Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment
Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...
Discussing Breast Density With Patients Following the FDA Mammography Quality Standards Act Mandate
In JAMA, Lee et al provided a concise, evidence-based summary to help clinicians discuss information regarding breast density and implement shared decision-making with patients following the U.S. Food and Drug Administration (FDA) Mammography Quality Standards Act mandate. Since September 2024,...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
Genetic Factors Could Illuminate Which Patients With Prostate Cancer Could Benefit From Combination of Ipatasertib Abiraterone
Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...
Consumer Survey Reveals Common Misconceptions About HPV and HPV-Related Cancer
A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
The Importance of Diversity in Clinical Research
The Cancer Drug Development Forum (CDDF) held its annual conference in the Netherlands from February 3–5, 2025. Under the title “Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials,” the workshop focused on diversity and real-world evidence in anticancer...
Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer
Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Long-term data from the phase...
Top Picks From SABCS 2024
Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...
BRCA1 Gene Mutations May Not Be Key to Prostate Cancer
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
ASCO Engages in Judicial and Legislative Advocacy to Protect NIH Funding
ASCO issued the following statement on February 21, 2025: "Cancer research is the core of ASCO’s mission and cancer cannot be conquered without continued robust federal investment for biomedical research through the National Institutes of Health (NIH) and the National Cancer Institute (NCI)....
Ageism and Its Role in the Treatment of Cancer
Age discrimination, often referred to as ageism, is an increasingly pressing issue within society. Although it can impact individuals across all age groups, older adults are particularly vulnerable. According to the U.S. Census Bureau projections, by 2040, individuals aged 65 and older will...
Darolutamide in Triple-Negative, AR-Positive Advanced Breast Cancer
In a French phase II trial (UCBG 3-06 START) reported in The Lancet Oncology, Bonnefoi et al found that treatment with the antiandrogen darolutamide did not reach the clinical benefit endpoint in patients with triple-negative, androgen receptor (AR)-positive advanced breast cancer. Triple-negative...
Influencing Geriatric Oncology Practice Worldwide: 2024 International Society of Geriatric Oncology Conference
The Annual Meeting of the International Society of Geriatric Oncology (SIOG) was held from October 17–19, 2024, in Montreal. The conference theme was “Promoting Equity and Enhancing Optimal Care Delivery.” The conference chairs were Shabbir Alibhai, MD, MSc, FRCPC, and Martine Puts, RN, PhD, FAAN,...
Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma
Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Cancer, Aging, and Meaning: Navigating Psychosocial Challenges
I’ve learned a lot about medicine over the years, but one thing I wasn’t taught was how to guide someone through the existential weight of dying. My education centered on diagnosing, curing, or at least managing disease—not on the delicate art of helping people and their loved ones cope with what...
Final Overall Survival Results From TALAPRO-2 in Unselected Patients With Metastatic Castration-Resistant Prostate Cancer
The final overall survival results from cohort 1 of the phase III TALAPRO-2 trial showed a statistically significant and clinically meaningful improvement with the PARP inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide vs standard-of-care enzalutamide in treatment-naive...
I’m a 2.0 Version of Myself After Cancer
Although there’s no history of breast cancer in my family, when I was 10, my pediatrician introduced me to breast self-exams, so I would become familiar with my breasts and learn to spot any unusual changes as I got older. I remember her telling me this was an especially important exercise to do...
How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer
Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...
ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
ASCO has updated its guidelines on the role of neoadjuvant chemotherapy for patients newly diagnosed with advanced ovarian cancer, underscoring key considerations in selecting patients for treatment and where to go from there.1 Since ASCO’s previous guidelines were published in 2016, there has been ...
Mobocertinib vs Platinum-Based Chemotherapy in First-Line Treatment of EGFR Exon 20 Insertion–Positive Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Jänne et al, an interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib—an EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion (ex20ins) mutations—compared with...
Lung-MAP 3.0: Simplifying the Process to Meet Patients’ Needs
The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-line therapy. This pioneering effort was the first biomarker-driven umbrella master protocol...
Does Epstein-Barr Virus Increase Cancer Risk Among Kidney Transplant Recipients?
Kidney transplantation using donor organs carrying the Epstein-Barr virus may increase the risk of posttransplant lymphoproliferative disorder among recipients who have never been exposed to the virus, according to a recent study published by Potluri et al in the Annals of Internal Medicine....
Anticancer Drug Pharmacokinetics May Differ by Sex
Investigators may have uncovered notable pharmacokinetic differences between male and female patients in at least 14 anticancer drugs, according to a recent study published by Delahousse et al in ESMO Open. Background Many cancer drugs have a narrow therapeutic window. As a result, slight...
In Case You Missed It: Additional Studies of Interest From ASH 2024
A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...
Using AI to Identify Treatment Options for Castleman Disease
A novel artificial intelligence (AI) tool uncovered an effective treatment for a patient with idiopathic multicentric Castleman’s disease, according to a recent study published by Mumau et al in The New England Journal of Medicine. Background Idiopathic multicentric Castleman’s disease is a rare...
Triplet for Untreated TP53-Mutated Mantle Cell Lymphoma
First-line treatment with the Bruton’s tyrosine kinase inhibitor zanubrutinib plus the anti-CD20 monoclonal antibody obinutuzumab and the BCL2 inhibitor venetoclax appeared to be safe and active in previously untreated patients with TP53-mutated mantle cell lymphoma, based on the results of the...
Is Clonal Cytopenia of Undetermined Significance Distinct From Lower-Risk Myelodysplastic Syndrome?
High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informative with regard to prognosis, management, and clinical trial eligibility, said Zhuoer (Zoey) Xie, MD, ...
Potential Link Between Early Side Effects From Radiation Therapy and Long-Term Side Effects in Patients With Prostate Cancer
The risk of developing more serious long-term urinary and bowel health issues may be higher in men undergoing radiation therapy for prostate cancer who experience side effects early in treatment, according to a recent study published by Nikitas et al in The Lancet Oncology. The findings highlighted ...
Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib showed that discontinuation of treatment—with resumption for progressive disease—was associated with...
AI May Boost Efficacy of Cancer Care, but Physicians Remain Critical to Decision-Making, Study Finds
Although artificial intelligence (AI)-assisted radiotherapy may help physicians make more informed decisions when treating patients with cancer, there may be challenges in how physicians work with the technology, according to a recent study published by Niraula et al in Nature Communications. Study ...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Young Patients With Cancer Living in Historic Redlined Neighborhoods Are Dying at Higher Rates Than Those in Nonredlined Areas
Studies have shown that adults living in historically redlined neighborhoods are less likely to be screened for breast, colorectal, and cervical cancers and have worse survival than those living in nonredlined areas. Redlining, a discriminatory, racist practice that began in the 1920s and 1930s in...
Study Finds Therapeutic Vaccine Targeting HPV16 Is Safe and Effective in Eradicating Precancerous Cervical Lesions
The investigational therapeutic vaccine Vvax001 was found to be safe and showed preliminary clinical effectiveness in a phase II clinical trial of patients with HPV16-positive grade 3 cervical intraepithelial neoplasia. If confirmed in a phase III trial, the vaccine may provide a nonsurgical option ...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
ChatGPT Has Limitations in Clinical Utility for Colorectal Cancer but May Be Useful for Patient Education
A study evaluating ChatGPT’s ability to accurately respond to patient inquiries regarding colon cancer by comparing its responses with assessments from expert clinical oncologists found that questions about symptoms, prevention, and screening for the cancer were highly accurate. However, responses...
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI
ASCO has applauded Monica M. Bertagnolli, MD, FASC, FASCO, for her service as the 17th Director of the National Institutes of Health (NIH) and Kimryn Rathmell, MD, PhD, for her work as the 17th Director of the National Cancer Institute (NCI). “ASCO would like to extend our deepest gratitude to Dr....
AACR Expresses Sincere Appreciation After NIH Director Monica M. Bertagnolli, MD, Steps Down
The American Association for Cancer Research (AACR) expressed its gratitude to Monica M. Bertagnolli, MD, for her outstanding service to the United States during her 14-month tenure as Director of the National Institutes of Health (NIH). Background Dr. Bertagnolli recently announced that she will...
